- South Korea
- /
- Personal Products
- /
- KOSDAQ:A052260
Impressive Earnings May Not Tell The Whole Story For HYUNDAI BIOLANDLtd (KOSDAQ:052260)
HYUNDAI BIOLAND Co.,Ltd's (KOSDAQ:052260) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details.
See our latest analysis for HYUNDAI BIOLANDLtd
The Impact Of Unusual Items On Profit
To properly understand HYUNDAI BIOLANDLtd's profit results, we need to consider the ₩3.2b gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that HYUNDAI BIOLANDLtd's positive unusual items were quite significant relative to its profit in the year to December 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of HYUNDAI BIOLANDLtd.
Our Take On HYUNDAI BIOLANDLtd's Profit Performance
As previously mentioned, HYUNDAI BIOLANDLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that HYUNDAI BIOLANDLtd's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The good news is that, its earnings per share increased by 69% in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. When we did our research, we found 3 warning signs for HYUNDAI BIOLANDLtd (1 can't be ignored!) that we believe deserve your full attention.
This note has only looked at a single factor that sheds light on the nature of HYUNDAI BIOLANDLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
Valuation is complex, but we're here to simplify it.
Discover if HYUNDAI BIOLANDLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A052260
HYUNDAI BIOLANDLtd
Engages in the manufacture and sale of natural materials for cosmetics, nutraceuticals, and regenerative medicines worldwide.
Solid track record with excellent balance sheet.